Rapid platelet-function assay an automated and quantitative cartridge- based method

Circulation

Volumn 99, Issue 5, 1999, Pages 620-625

  Smith, Jeffrey W ^a   Steinhubl, Steven R ^b   Lincoff, A Michael ^b   Coleman, Jacqueline C ^a   Lee, Theodore T ^a   Hillman, Robert S ^a   Coller, Barry S ^c  

^a Accumetrics Inc   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs; Glycoproteins; Platelets

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; THROMBIN RECEPTOR;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING PARAMETERS; DRUG MONITORING; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; LABORATORY TEST; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECEPTOR BLOCKING; THROMBOCYTE FUNCTION; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

EID: 0033537494     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.5.620     Document Type: Article

References (12)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation. 1997;96:76-81.
3. Cannon CP, McCabe CH, Borzak S, Henry TC, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, for the TIMI 12 Investigators. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-349.
4. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation. 1998;97: 312-314.
5. Coller BS, Lang D, Scudder LE. A rapid and simple platelet function assay to assess GP IIb/IIIa receptor blockade. Circulation. 1997;95: 860-867.
6. Coller BS, Springer KT, Scudder LE, Kutok JL, Ceruso M, Prestwich GD. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem. 1993;268:20741-20743.
7. Sugihara H, Fukushi H, Miyawaki T, Imai Y, Terashita Z, Kawamura M, Fujisawa Y, Kita S. Novel non-peptide fibrinogen receptor antagonists, I: synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J Med Chem. 1998;41:489-502.
8. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Med. 1949;51:660-672.
9. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
10. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation. 1998;97:5-9.
11. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen K, Stibbe J, de Feyter PJ, the European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
12. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention. Circulation. 1996;94:906-910.